CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker

Vandana Singh
1 min read
0
In this article:

  • Moderna Inc (NASDAQ: MRNA) and CytomX Therapeutics Inc (NASDAQ: CTMX) announced a collaboration and licensing agreement to create mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform.

  • Under the terms of the agreement, CytomX will receive an upfront payment of $35 million, including $5 million of pre-paid research funding.

  • CytomX will continue to receive research funding and is eligible to receive up to approximately $1.2 billion in future development, regulatory, and commercial milestone payments.

  • CytomX is also eligible to receive tiered royalties on global net sales of any products that are commercialized under the agreement.

  • Moderna and CytomX will collaborate on the discovery and pre-clinical development, and Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement.

  • The agreement additionally provides Moderna with an option to participate in future equity financing by CytomX.

  • In November, CytomX announced an agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) for conditionally-activated bispecific cancer therapies.

  • Price Action: CTMX shares are up 45.30% at $2.60 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories